Literature DB >> 11353654

In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers.

A L Barry1, P C Fuchs, S D Brown.   

Abstract

The in vitro activity of daptomycin is affected by the concentration of calcium cations in the test medium. Mueller-Hinton broth is currently adjusted to contain 10 to 12.5 mg of magnesium per liter and 20 to 25 mg of calcium per liter, but for testing of daptomycin, greater concentrations of calcium (50 mg/liter) are recommended to better resemble the normal concentration of ionized calcium in human serum. Two levels of calcium were used for broth microdilution tests of 2,789 recent clinical isolates of gram-positive bacterial pathogens. MICs of daptomycin were two- to fourfold lower when the broth contained additional calcium. For most species, however, the percentages of strains that were inhibited by 2.0 microg of daptomycin per ml were essentially identical with the two broth media. Enterococci were the important exception; i.e., 92% were inhibited when tested in calcium-supplemented broth but only 35% were inhibited by 2.0 microg/ml without the additional calcium. This type of information should be considered when selecting criteria for defining in vitro susceptibility to daptomycin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11353654      PMCID: PMC90574          DOI: 10.1128/AAC.45.6.1919-1922.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Diagn Microbiol Infect Dis       Date:  2000-09       Impact factor: 2.803

2.  Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

3.  In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.

Authors:  G M Eliopoulos; S Willey; E Reiszner; P G Spitzer; G Caputo; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

4.  Daptomycin: a novel agent for Gram-positive infections.

Authors:  F P Tally; M Zeckel; M M Wasilewski; C Carini; C L Berman; G L Drusano; F B Oleson
Journal:  Expert Opin Investig Drugs       Date:  1999-08       Impact factor: 6.206

5.  Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations.

Authors:  D E Low; A McGeer; R Poon
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

6.  Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits.

Authors:  S Kennedy; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

7.  Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia.

Authors:  M J Rybak; E M Bailey; K C Lamp; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

8.  Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci.

Authors:  M C Ramos; M L Grayson; G M Eliopoulos; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

9.  Susceptibility testing of clinical isolates of Enterococcus faecium and Enterococcus faecalis.

Authors:  M Louie; A E Simor; S Szeto; M Patel; B Kreiswirth; D E Low
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

  9 in total
  45 in total

1.  In vitro activities of a new lipopeptide, HMR 1043, against susceptible and resistant gram-positive isolates.

Authors:  Pascale Bemer; Marie-Emmanuelle Juvin; Andre Bryskier; Henri Drugeon
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

2.  In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants.

Authors:  Ad C Fluit; Franz-Josef Schmitz; Jan Verhoef; Dana Milatovic
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  Inactivation of the lipopeptide antibiotic daptomycin by hydrolytic mechanisms.

Authors:  Vanessa M D'Costa; Tariq A Mukhtar; Tejal Patel; Kalinka Koteva; Nicholas Waglechner; Donald W Hughes; Gerard D Wright; Gianfranco De Pascale
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

Review 4.  Bloodstream infections in the Intensive Care Unit.

Authors:  Matteo Bassetti; Elda Righi; Alessia Carnelutti
Journal:  Virulence       Date:  2016-01-13       Impact factor: 5.882

5.  In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains.

Authors:  Bram M W Diederen; Inge van Duijn; Piet Willemse; Jan A J W Kluytmans
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 6.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

7.  Assessment of two commercial susceptibility test methods for determination of daptomycin MICs.

Authors:  James H Jorgensen; Sharon A Crawford
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

8.  Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Brian T Tsuji; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

9.  Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis.

Authors:  Philippe Cottagnoud; Marc Pfister; Fernando Acosta; Marianne Cottagnoud; Lukas Flatz; Felix Kühn; Hans-Peter Müller; Armin Stucki
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 10.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.